Trial Title:
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
NCT ID:
NCT06295809
Condition:
Carcinoma, Squamous Cell
Skin Neoplasms
Conditions: Official terms:
Carcinoma
Carcinoma, Squamous Cell
Skin Neoplasms
Pembrolizumab
Conditions: Keywords:
pembrolizumab
Study type:
Interventional
Study phase:
Phase 2/Phase 3
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
In the Phase 2 of the study design, approximately 600 participants will be randomly
assigned into 3 arms in an approximate 5:5:2 ratio (250 to V940 plus pembrolizumab with
SOC, 250 participants to SOC only, and 100 participants to pembrolizumab monotherapy with
SOC). If the decision is made to expand the study to Phase 3, the 600 participants
enrolled in Phase 2 will keep their originally assigned study intervention arms in the
Phase 3 Expansion, and 412 new participants will be enrolled and randomly assigned in a
1:1 ratio to receive treatment with either V940 plus pembrolizumab with SOC or SOC only.
New participants will not be randomized into the pembrolizumab monotherapy with SOC arm
during the Phase 3 Expansion.
Primary purpose:
Treatment
Masking:
Single (Outcomes Assessor)
Intervention:
Intervention type:
Biological
Intervention name:
Pembrolizumab
Description:
IV Infusion
Arm group label:
Pembrolizumab plus V940 with SOC
Arm group label:
Pembrolizumab with SOC
Other name:
MK-3475
Other name:
Keytruda®
Intervention type:
Biological
Intervention name:
V940
Description:
IM injection
Arm group label:
Pembrolizumab plus V940 with SOC
Other name:
mRNA-4157
Intervention type:
Procedure
Intervention name:
Surgery
Description:
Local resection of cancerous lesions of the skin
Arm group label:
Pembrolizumab plus V940 with SOC
Arm group label:
Pembrolizumab with SOC
Arm group label:
Standard of Care (SOC)
Summary:
This is a two-part (Phase 2/Phase 3) study of V940, an individualized neoantigen therapy
(INT), plus pembrolizumab in participants with locally resectable advanced cutaneous
squamous cell carcinoma (LA cSCC). Phase 2 has three arms V940 plus pembrolizumab given
as neoadjuvant and adjuvant treatment with standard of care (SOC), standard of care
(surgical resection with/without adjuvant radiation therapy (RT) only at investigator's
discretion) and pembrolizumab monotherapy given as neoadjuvant and adjuvant treatment
with SOC. This phase will assess the safety and efficacy of V940 in combination with
pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC
as compared to standard of care SOC only. The primary hypothesis is that V940 plus
pembrolizumab with SOC is superior to SOC only with respect to event free survival (EFS)
as assessed by the investigator. Phase 3 expansion will be determined by prespecified
Go-No-Go decision in which 412 additional participants will be randomized to V940 plus
pembrolizumab with SOC and SOC only, without changing the inclusion/exclusion criteria
for the additional enrollment or study endpoints.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Has a histologically confirmed diagnosis of resectable cSCC as the primary site of
malignancy (metastatic skin involvement from another primary cancer or from an
unknown primary cancer is not permitted)
- Has LA Stage II-IV (M0) cSCC without distant metastases
- cSCC must be amenable to surgery (resectable) with curative intent
- Has a formalin-fixed, paraffin-embedded (FFPE) tumor sample available or is able to
provide one that is suitable for the Next-generation Sequencing (NGS) required for
this study
- For males, agrees to be abstinent from penile-vaginal intercourse OR agrees to use a
highly effective contraceptive method while receiving adjuvant radiation therapy
(RT), and for ≥3 months after the last dose of study intervention
- Is female and not pregnant/breastfeeding and at least one of the following applies
during the study : is not a woman of childbearing potential (WOCBP), is a WOCBP and
uses highly effective contraception (low user dependency method OR a user dependent
hormonal method in combination with a barrier method) at least during use of V940:
15 days, Pembrolizumab: 120 days, Adjuvant RT, if performed: 90 days after last
exposure or is a WOCBP who is abstinent from heterosexual intercourse
- Has measurable disease per RECIST 1.1 as assessed by the local site
investigator/radiology
- Has a life expectancy of >3 months per investigator assessment
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
assessed within 14 days before randomization
- Has adequate organ function
- If hepatitis B surface antigen (HBsAg) positive must have received hepatitis B virus
(HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
prior to randomization
- If there is a history of hepatitis C virus (HCV) infection, HCV viral load must be
undetectable at screening
- If human immunodeficiency virus (HIV)-infected, must have well controlled HIV on
antiretroviral therapy (ART)
Exclusion Criteria:
- Has any other histologic type of skin cancer other than invasive cSCC as well as
mixed histology, eg, basal cell carcinoma that has not been definitively treated
with surgery or radiation, Bowen's disease, Merkel cell carcinoma (MCC), or melanoma
- Has distant metastatic disease (M1), visceral and/or distant nodal
- Has received prior therapy with an anti-programmed cell death receptor 1
(anti-PD-1), anti-programmed cell death receptor ligand 1 (anti-PD-L1), or
anti-programmed cell death receptor ligand 2 (anti-PD-L2) agent, or with an agent
directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic
T-lymphocyte associated protein 4 (CTLA-4), OX-40, CD137)
- Has received prior systemic anticancer therapy including investigational agents for
cSCC before randomization
- Has received prior radiotherapy within 2 weeks of start of study intervention, or
has radiation-related toxicities, requiring corticosteroids
- Has received a live or live-attenuated vaccine within 30 days before the first dose
of study intervention
- Has received transfusion of blood products (including platelets or red blood cells)
or administration of colony stimulating factors (including granulocyte
colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or
recombinant erythropoietin) within 2 weeks of the screening blood sample (including
the NGS blood sample)
- Has received prior treatment with another cancer vaccine
- Has received prior radiotherapy to the index lesion (in-field lesion). Must have
recovered from all radiation-related toxicities prior to randomization and not have
had radiation pneumonitis
- Has received an investigational agent or has used an investigational device within 4
weeks prior to study intervention administration
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior the first dose of study medication
- Has a known additional malignancy that is progressing or has required active
treatment within the past 2 years
- History of chronic lymphocytic leukemia (CLL)
- History of central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has severe hypersensitivity (≥Grade 3) to either V940 or pembrolizumab and/or any of
its excipients
- Has an active autoimmune disease that has required systemic treatment in the past 2
years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid)
is allowed
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required
steroids or has current pneumonitis/interstitial lung disease
- Has an active infection requiring systemic therapy
- Has HIV with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV
DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA)
infection
- Has had a myocardial infarction within 6 months of randomization
- Has a history of allogeneic tissue/solid organ transplant
- Has not adequately recovered from major surgery or have ongoing surgical
complications
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Winship Cancer Institute, Emory University ( Site 1151)
Address:
City:
Atlanta
Zip:
30322
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
202-441-6171
Facility:
Name:
University of Iowa-Holden Comprehensive Cancer Center ( Site 1118)
Address:
City:
Iowa City
Zip:
52242
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
319-356-1032
Facility:
Name:
University of Kentucky Chandler Medical Center ( Site 1101)
Address:
City:
Lexington
Zip:
40536
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
859-257-9568
Facility:
Name:
Ochsner Clinic Foundation ( Site 1113)
Address:
City:
New Orleans
Zip:
70121
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
504-842-3910
Facility:
Name:
Washington University School of Medicine-Internal Medicine/Oncology ( Site 1100)
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
314-362-5677
Facility:
Name:
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1125)
Address:
City:
Hackensack
Zip:
07601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
551-996-5814
Facility:
Name:
Atlantic Health System Morristown Medical Center ( Site 1136)
Address:
City:
Morristown
Zip:
07960
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
973-971-7111
Facility:
Name:
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1160)
Address:
City:
Mineola
Zip:
11501
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
212-731-5431
Facility:
Name:
Laura and Isaac Perlmutter Cancer Center ( Site 1121)
Address:
City:
New York
Zip:
10016
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
212-731-5431
Facility:
Name:
Providence Portland Medical Center ( Site 1102)
Address:
City:
Portland
Zip:
97213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
503-215-5696
Facility:
Name:
UPMC Hillman Cancer Center ( Site 1107)
Address:
City:
Pittsburgh
Zip:
15232
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
412-623-7368
Facility:
Name:
Avera Cancer Institute- Research ( Site 1161)
Address:
City:
Sioux Falls
Zip:
57105
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
605-838-5945
Facility:
Name:
University of Virginia Health System ( Site 1115)
Address:
City:
Charlottesville
Zip:
22908
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
434-305-9715
Facility:
Name:
University Hospital and UW Health Clinics ( Site 1119)
Address:
City:
Madison
Zip:
53792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
608-234-4385
Facility:
Name:
Fundacion Estudios Clinicos-Oncology ( Site 1205)
Address:
City:
Rosario
Zip:
S2000DEJ
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+5493469699922
Facility:
Name:
Hospital Italiano de Córdoba ( Site 1204)
Address:
City:
Cordoba
Zip:
X5004BAL
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
3515054293
Facility:
Name:
Melanoma Institute Australia-Clinical Trials Unit ( Site 3205)
Address:
City:
Wollstonecraft
Zip:
2065
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
61299117336
Facility:
Name:
Sunshine Coast University Hospital-Medical Oncology ( Site 3212)
Address:
City:
Birtinya
Zip:
4575
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
52021111
Facility:
Name:
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
Address:
City:
Brisbane
Zip:
4029
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
61736468111
Facility:
Name:
Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 3207)
Address:
City:
Gold Coast
Zip:
4215
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
61421375349
Facility:
Name:
Gallipoli Medical Research Ltd-GMRF CTU ( Site 3206)
Address:
City:
Greenslopes
Zip:
4120
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
61731766577
Facility:
Name:
Austin Health ( Site 3209)
Address:
City:
Heidelberg
Zip:
3084
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
0416335678
Facility:
Name:
One Clinical Research ( Site 3211)
Address:
City:
Nedlands
Zip:
6009
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+61862799466
Facility:
Name:
Cliniques universitaires Saint-Luc ( Site 1701)
Address:
City:
Brussels
Zip:
1200
Country:
Belgium
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
3227645471
Facility:
Name:
Associação Hospitalar Beneficente São Vicente de Paulo-Instituto do Câncer ( Site 1309)
Address:
City:
Passo Fundo
Zip:
99010-080
Country:
Brazil
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
555421033490
Facility:
Name:
Jewish General Hospital ( Site 1009)
Address:
City:
Montreal
Zip:
H3T 1E2
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
514-340-8222 x24572
Facility:
Name:
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer
Address:
City:
Sherbrooke
Zip:
J1H 5H4
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
819346111074816
Facility:
Name:
James Lind Centro de Investigacion del Cancer ( Site 1411)
Address:
City:
Temuco
Zip:
4800827
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+56994443272
Facility:
Name:
CIDO SpA-Oncology ( Site 1405)
Address:
City:
Temuco
Zip:
4810218
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
569 5 798 31 73
Facility:
Name:
FALP-UIDO ( Site 1401)
Address:
City:
Santiago
Zip:
7500921
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
56224457254
Facility:
Name:
Clínica Alemana de Santiago-Gynecology and Obstetrics ( Site 1410)
Address:
City:
Santiago
Zip:
7650568
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
56985008201
Facility:
Name:
Fundacion Colombiana de Cancerología Clinica Vida ( Site 1501)
Address:
City:
Medellín
Zip:
050030
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
573126867004
Facility:
Name:
Oncologos del Occidente ( Site 1504)
Address:
City:
Pereira
Zip:
660001
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+573154208077
Facility:
Name:
Fundación Valle del Lili ( Site 1502)
Address:
City:
Cali
Zip:
760032
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
57 3162801914
Facility:
Name:
CHU de Bordeaux Hop St ANDRE ( Site 1902)
Address:
City:
Bordeaux
Zip:
33075
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+33557822521
Facility:
Name:
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 1903)
Address:
City:
Marseille
Zip:
13005
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+33491388801
Facility:
Name:
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1904)
Address:
City:
Dijon
Zip:
21000
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
33380293336
Facility:
Name:
Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE ( Site 1908)
Address:
City:
Toulouse
Zip:
31059
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
33531155675
Facility:
Name:
Gustave Roussy ( Site 1909)
Address:
City:
Villejuif
Zip:
94800
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
33142114210
Facility:
Name:
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu-Onco-Dermatology ( Site 1910)
Address:
City:
Nantes
Zip:
44093
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
02 40 08 31 44
Facility:
Name:
Hopital Claude Huriez - CHU de Lille ( Site 1907)
Address:
City:
Lille
Zip:
59037
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
33320444193
Facility:
Name:
centre hospitalier lyon sud ( Site 1901)
Address:
City:
Pierre-Bénite
Zip:
69310
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+33478861679
Facility:
Name:
Hôpital Saint-Louis ( Site 1906)
Address:
City:
Paris
Zip:
75475
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
33142499595
Facility:
Name:
NCT ( Site 2002)
Address:
City:
Heidelberg
Zip:
69120
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
06221-5638503
Facility:
Name:
Klinikum Dortmund Klinikzentrum Mitte ( Site 2008)
Address:
City:
Dortmund
Zip:
44137
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+49 152 21477812
Facility:
Name:
Universitätsmedizin Johannes Gutenberg Universität Mainz ( Site 2007)
Address:
City:
Mainz
Zip:
55131
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
496131177112
Facility:
Name:
Universitätsklinikum Schleswig-Holstein-Dermatology ( Site 2012)
Address:
City:
Lubeck
Zip:
23538
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
49 173 547 9918
Facility:
Name:
Pécsi Tudományegyetem Klinikai Központ-Bőr-, Nemikórtani és Onkodermatológiai Klinika ( Site 2100)
Address:
City:
Pecs
Zip:
7632
Country:
Hungary
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+3672536882
Facility:
Name:
Debreceni Egyetem Klinikai Kozpont-Bőrgyógyászati Klinika ( Site 2102)
Address:
City:
Debrecen
Zip:
4032
Country:
Hungary
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
0036304374672
Facility:
Name:
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz- Onkoradiologiai Osztaly ( Site 2110)
Address:
City:
Gyor
Zip:
9024
Country:
Hungary
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
36964182446104
Facility:
Name:
Hadassah Medical Center ( Site 2201)
Address:
City:
Jerusalem
Zip:
9112001
Country:
Israel
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
97226777825
Facility:
Name:
Rabin Medical Center ( Site 2202)
Address:
City:
Petah Tikva
Zip:
4941492
Country:
Israel
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
97235305201
Facility:
Name:
Sheba Medical Center ( Site 2200)
Address:
City:
Ramat Gan
Zip:
5265601
Country:
Israel
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
97235307039
Facility:
Name:
Harbour Cancer & Wellness ( Site 3300)
Address:
City:
Auckland
Zip:
1023
Country:
New Zealand
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
6421783590
Facility:
Name:
Oslo universitetssykehus, Radiumhospitalet ( Site 2400)
Address:
City:
Oslo
Zip:
0379
Country:
Norway
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+4722934000
Facility:
Name:
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2501)
Address:
City:
Bydgoszcz
Zip:
85-796
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
48501446778
Facility:
Name:
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Address:
City:
Warszawa
Zip:
02-781
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
48226439375
Facility:
Name:
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 2506)
Address:
City:
Gdansk
Zip:
80-952
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
48585844571
Facility:
Name:
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch
Address:
City:
Kielce
Zip:
25-734
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+48604675789
Facility:
Name:
Centrum Medyczne HCP ( Site 2505)
Address:
City:
Poznań
Zip:
61-485
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
604116632
Facility:
Name:
Spitalul Universitar de Urgență Elias ( Site 2600)
Address:
City:
București
Zip:
011461
Country:
Romania
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+40748052052
Facility:
Name:
SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 2602)
Address:
City:
Florești
Zip:
407280
Country:
Romania
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
40742206212
Facility:
Name:
Centrul de Oncologie "Sfântul Nectarie"-Medical Oncology ( Site 2601)
Address:
City:
Craiova
Zip:
200542
Country:
Romania
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
40727774974
Facility:
Name:
Sigmedical Services SRL ( Site 2603)
Address:
City:
Suceava
Zip:
720214
Country:
Romania
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+40722423653
Facility:
Name:
Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 2804)
Address:
City:
Badalona
Zip:
08916
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34934978574
Facility:
Name:
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
Address:
City:
Barcelona
Zip:
08036
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34932275402
Facility:
Name:
Centro Oncologico de Galicia ( Site 2806)
Address:
City:
A Coruna
Zip:
15009
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
981287499
Facility:
Name:
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2801)
Address:
City:
Madrid
Zip:
28034
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
(+34) 913368263
Facility:
Name:
H.R.U Malaga - Hospital General ( Site 2805)
Address:
City:
Málaga
Zip:
29010
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34951291425
Facility:
Name:
Hospital General Universitario de Valencia-oncology service ( Site 2802)
Address:
City:
Valencia
Zip:
46014
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34963131800437635
Facility:
Name:
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2803)
Address:
City:
Barcelona
Zip:
08035
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
349327460004350
Facility:
Name:
Clinica Universidad de Navarra-Medical Oncology ( Site 2807)
Address:
City:
Madrid
Zip:
28027
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
913531920
Facility:
Name:
Derriford Hospital-Oncology ( Site 3104)
Address:
City:
Plymouth
Zip:
Pl6 8DH
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
01752872475
Facility:
Name:
Castle Hill Hospital ( Site 3102)
Address:
City:
Cottingham
Zip:
HU16 5JQ
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
07395808710
Start date:
April 18, 2024
Completion date:
May 6, 2033
Lead sponsor:
Agency:
Merck Sharp & Dohme LLC
Agency class:
Industry
Collaborator:
Agency:
ModernaTX, Inc.
Agency class:
Industry
Source:
Merck Sharp & Dohme LLC
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06295809
https://www.merckclinicaltrials.com/
https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=V940-007&&kw=V940-007
